The study is conducted in healthy Thai subjects to evaluate the bioequivalence of two formulations of eltrombopag 25-mg film-coated tablets, REVOLADE 25 mg (Reference) and Eltrombopag Tablets 25 mg (Test), after a single oral dose administration bioequivalence, pharmacokinetics, eltrombopag
Conditions
Interventions
Generic eltrombopag olamine equivalent to eltrombopag 25-mg film-coated tablets manufactured by Dr. Reddy'
s Laboratories Limited. Eltrombopag Tablets 25 mg will be
administered along with 240 mL of drinking water after an overnight fasting of at least 10 hours.,Innovator eltrombopag olamine equivalent to
Active Comparator Drug,Active Comparator Drug
Eltrombopag Tablets 25 mg,REVOLADE 25 mg
Sponsors
Dr. Reddy's Laboratories Limited
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Thai Male/Female must be 18-55 years of age, BMI = 18.0-30.0 kg/m2 , inclusive. 2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 and not over 139 mmHg, diastolic blood pressure not lower than 60 and not over 89 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 3. Screening ECG without clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 4. Screening visit laboratory values of blood test including hematology (CBC with differential), FBS, BUN, Cr and liver function test (AST, ALT, total bilirubin and ALP) must be within the normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians. 5. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 6. Must have serum HBsAg, anti-HCV and anti-HIV negative 7. Female subject must have serum beta-hCG within normal range of non-pregnant woman or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians. 8. Female subject of childbearing potential or male subject agrees to use an acceptable birth control method from Screening Visit to the Follow-up Visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from Screening Visit to Follow-up Visit. Hormonal contraceptives are not acceptable. 9. Female subject of non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)) 10. Female subject must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at each period. 11. Non-smoker (never smoked or no smoking within the previous 1 year as judged by medical history) 12. Refrain from using herbal medications, cannabis containing products, dietary supplements (e.g., St. John's Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of investigational product (Day 1). Subjects must agree to refrain from these items until the last collection time-point of Period 2. 13. Subject must have ended any systemic medications or any medications that have any impact on gastrointestinal system at least 30 days prior to Day 1 or at least 7 times of elimination half-life prior to Day 1 and agree to continue their refraining throughout the follow-up period. 14. Subject must refrain from drinking caffeine and alcohol for at least 72 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of Period 2. 15. Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to eltrombopag or any other similar class of drugs or its components 2. Past medical history of renal and hepatic insufficiency 3. Subject has a history of any illness that, in the opinion of Principal/Clinical Investigator or designated physicians, might confound the result of the study or pose an additional risk in administering investigational product to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements. 4. Have history or presence of any thrombotic or thromboembolic complication or myelodysplastic syndrome 5. Have history of drug abuse (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months 6. Have positive result of urine drug abuse testing on opioids (Mor, MTD), cannabinoids (THC), Meth, Coc or MDMA at Screening Visit or before dose administration at each period 7. Alcohol abuse or excessive use (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months 8. Have positive result of alcohol breathing test at Screening Visit or before dose administration at each period 9. Female subject is pregnant or breast feeding. 10. Difficulties fasting or consuming standard meals 11. Difficulties swallowing whole film-coated tablet 12. Donation or loss of whole blood: a. greater than or equal to 50 mL and less than or equal to 499 mL within 30 days prior to Day 1 b. greater than or equal to 500 mL within 56 days prior to Day 1 13. Participation in any investigational drug study within 30 days from Screening Visit (from the last Follow-up Visit of the previous study to Screening Visit of this study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| area under the concentration-time profile to the last quantifiable concentration (AUC0-t) pre-dose and 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours post-dose Eltrombopag will be measured by ultra high performance liquid chromatography coupled to a tandem mass spectrometry (UHPLC/MS/MS) method,maximum concentration (Cmax) pre-dose and 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00 and 96.00 hours post-dose measured by ultra high performance liquid chromatography coupled to a tandem mass spectrometry (UHPLC/MS/MS) method | — |
Secondary
| Measure | Time frame |
|---|---|
| safety of eltrombopag in healthy Thai subjects AEs will be collected after first dose administration to Follow-up Visit AEs report | — |
Countries
Thailand
Contacts
Public ContactAriya Khunvichai
Medica Innova Co., Ltd.
Outcome results
None listed